MHRA approves cabotegravir - new medicine formulations for HIV prevention

Two new formulations cabotegravir (cabotegravir extended-release injectable suspension and tablets) have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). The treatment consists of Apretude 30mg film-coated tablets and Apretude 600mg prolonged-release suspension for injection. These treatments are indicated for the prevention of sexually transmitted HIV-1 infection — pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35kg with a higher infection risk, MHRA confirmed.

Additional informaiton to the following link: MHRA approves new medicine formulations for HIV prevention (europeanpharmaceuticalreview.com)